

intestinal tract frequently occurred in the mice which died following irradiation and saline injection.

1. Warren, S. L., and Whipple, G. H., *J. Exp. Med.*, 1923, v38, 713.
2. Chrom, S. A., *Acta Radiol.*, 1935, v16, 641.
3. Lawrence, J. H., and Tennant, R., *J. Exp. Med.*, 1937, v66, 667.
4. Furth, F. W., Coulter, M. P., and Howland, J. W., *Am. J. Path.*, 1952, v28, 171.
5. Miller, C. P., Hammond, C. W., and Tompkins, M., *Science*, 1950, v111, 540.
6. ———, *J. Lab. Clin. Med.*, 1951, v38, 331.

7. Miller, C. P., Hammond, C. W., Tompkins, M., and Shorter, G., *J. Lab. Clin. Med.*, 1952, v39, 462.
8. Furth, F. W., Coulter, M. P., and Howland, J. W., *Am. J. Path.*, 1952, v28, 25.
9. Shechmeister, I. L., and Bond, V. P., *Proc. Soc. Exp. Biol. and Med.*, 1951, v77, 77.
10. Shechmeister, I. L., Paulissen, L. J., and Fishman, M., *Fed. Proc.*, 1952, v11, 146.
11. Stuart, C. A., Personal Communication, 1952.
12. Gowen, J. W., and Zelle, M. R., *J. Infect. Dis.*, 1945, v77, 85.
13. Shechmeister, I. L., Bond, V. P., and Swift, M. N., *J. Immunol.*, 1952, v68, 87.

Received July 14, 1952. P.S.E.B.M., 1952, v80.

Effects of the Hyperglycemic-Glycogenolytic Factor (HGF), Epinephrine and Insulin in Normal and Depancreatized Dogs.* (19715)

PIERO P. FOÁ, LEONIDA SANTAMARIA,[†] SHELDON BERGER, JAY A. SMITH,
AND HARRIET R. WEINSTEIN.[‡]

*From the Department of Physiology and Pharmacology, The Chicago Medical School,
710 South Wolcott Ave., Chicago, Illinois.*

During the course of experiments designed to study the action of certain insulin-free pancreatic extracts on the ketonemia and ketonuria of depancreatized dogs, it was noticed that the extracts had a marked hyperglycemic effect(1), probably because they contained the hyperglycemic-glycogenolytic factor (HGF). The extent of the hyperglycemia and its duration in different animals were extremely variable, however, even when the extracts were derived from the same batch of pancreas, were treated in the same manner and were injected under apparently identical conditions. Other experiments showed that the injection of epinephrine into depancreatized dogs with ketosis was also followed by a variable hyperglycemic response. The work described in this paper was undertaken to investigate the reasons for this variability.

Materials and methods. Well-fed mongrel dogs were depancreatized aseptically under

sodium pentobarbital anesthesia. Following the operation, 100 ml of 0.9% saline, 100 ml of 10% glucose, 10 units of regular insulin (Lilly) and 30,000 of slow-acting penicillin were injected subcutaneously. This treatment was repeated on the first and, occasionally, on the second postoperative day. Penicillin injections were continued for 7 to 10 days. As soon as the animals started to eat, protamine zinc insulin (Lilly) was given instead of regular insulin. On the 7th postoperative day, the abdominal incision showed satisfactory healing and the stitches were removed. The dogs were kept in metabolism cages and fed the following daily ration: raw pancreas 100 g, sucrose 40 g, raw horse meat 500 to 700 g, depending upon the size of the animal. The urine was collected daily and the 24-hour glucose excretion was determined quantitatively; urinary ketone bodies were estimated according to an arbitrary scale (1+ to 4+) using Acetest[§] tablets. The dogs were weighed once a week until the dietary and insulin requirements had been determined and

* Supported by a grant from Eli Lilly and Co.

[†] Fulbright Fellow. Present address: Istituto di Patologia Generale, Università di Perugia, Italy.

[‡] Present address: Highland Alameda County Hospital, Oakland, Calif.

[§] Acetest Tablets were donated by the Ames Co., Elkhart, Ind.

TABLE I. Maximum Blood Sugar Rise Following Intravenous Injection of "Crude" HGF Extract in Depancreatized Dogs with Ketosis.

Group 1—"Mild" ketosis				Group 2—"Severe" ketosis			
Max blood sugar rise				Max blood sugar rise			
No.	Initial blood ketones, mg %	mg	% of initial value	No.	Initial blood ketones, mg %	mg	% of initial value
1	0	71.8	46.7	20	30.2	62.3	18.7
2	3.9	32.6	46.7	21	38.1	7.8	20
3	4.5	151.3	73.7	22	38.3	27.1	26.4
4	5.2	33.3	39	23	41.5	83.1	22.2
5	5.9	200.9	55	24	42.6	45.4	25.2
6	6.5	40	44.6	25	44.8	114.3	40
7	7	89.1	55.8	26	61.6	65.9	17.1
8	9.5	76.6	22.5	27	63.8	117.3	61.3
9	13.2	49.5	89.6	28	69.4	86.3	44.4
10	13.4	134.7	38.5	29	75.1	33	11.9
11	14.4	34.2	40.5	30	82.3	22.3	12.5
12	15.6	64.5	74.3	31	84	26	19.6
13	18.9	36.8	62.3	32	94.5	26.1	7.5
14	19	62.1	31	33	96.3	32	6.5
15	19.7	73.9	56.8	34	106.4	180.3	52.3
16	22.4	44	38.6	35	187.5	33.4	35.6
17	24.6	151.3	30.6				
18	26	48.8	18.9				
19	29.1	191.5	47.2				
Avg	13.6	81.5	48	Avg	72.2	60.9	26.3

$\uparrow$ $P < .01$ $\uparrow$
 $P < .01$

the animals had regained their preoperative weight, then at longer intervals. Protamine zinc insulin was administered at feeding time in doses sufficient to keep the urine acetone-free, the 24-hour glucose excretion below 10 g and the weight of the animal approximately constant. When an animal was needed for experiments, insulin was withdrawn until a strong (4+) ketonuria developed, usually 3 to 5 days. Quiet, well-fed mongrel dogs were used as controls. On the morning of an experiment the animals were not fed, control blood samples were taken, the extract containing HGF was injected intravenously and samples of blood were taken at various intervals of time for 4 hours. Blood ketone bodies were determined in duplicate following a modification of the method of Greenberg and Lester(2,3); blood glucose was determined in duplicate following the method of Folin and Malmrose(4). Urinary glucose was determined by means of Benedict's quantitative reagent. Two types of extracts containing HGF were used. The first one, which will be referred to as the "crude" HGF extract, was

prepared as follows: 5.0 g of "12.5% salt cake," obtained by Eli Lilly and Company during the process of insulin manufacture, were dissolved in 100 ml of 0.08 N NaOH; the solution was incubated at 39°C for 2 hours and the pH adjusted to 7.4 with dilute HCl. After filtration or centrifugation, the clear "crude" extract was injected intravenously in doses equivalent to 10 g of fresh pancreas per kilo of body weight. The second type of preparation was obtained by extracting lyophilized whole pancreas powder with liquid ammonia and purifying it partially by precipitation with 80% ethyl alcohol, according to a method described elsewhere(5). This preparation, dissolved in 10 ml of 0.9% saline, was injected in doses of 1 mg/kg and will be referred to as the "semi-purified" HGF. When indicated, the statistical significance of the results was calculated according to the method of Fisher(6) and expressed as "P", the probability that the results obtained might have been due to chance.

Results. The animals were listed in order of increasing concentration of ketones in the

TABLE II. Maximum Blood Sugar Rise Following Intravenous Injection of Epinephrine (.02 mg/kg) in Depancreatized Dogs with Ketosis.

Group 1—"Mild" ketosis				Group 2—"Severe" ketosis			
Max blood sugar rise				Max blood sugar rise			
No.	Initial blood ketones, mg %	mg	% of initial value	No.	Initial blood ketones, mg %	mg	% of initial value
1	5.4	65.1	25	6	31.4	22.2	14.3
2	10.7	95.3	58.3	7	71.7	8	2.7
3	13.4	76.2	27.6	8	88.5	11.6	3.4
4	17.1	65.9	53.8				
5	18.2	46.5	25.6				
Avg	12.9	68.9	38.1	Avg	63.9	13.9	6.7




FIG. 1

FIG. 1. Hyperglycemia produced by intravenous injection of "semi-purified" HGF (1 mg/kg). Average of 10 normal and 10 depancreatized dogs without ketosis.




FIG. 2

FIG. 2. Hypoglycemia produced by subcutaneous injection of regular insulin (.1 unit/kg). Average of 2 normal and 2 depancreatized dogs without ketosis.

their livers. A possible explanation is that, just as hyperglycemia produced by glucose administration stimulates the secretion of insulin by the pancreas of the normal animal (12-14), so the hyperglycemia produced by the injection of HGF might stimulate insulin secretion and thus, where a functioning pancreas is present, limit its own effect. Only in the depancreatized animal could HGF exert its full action. The observation that insulin has a greater effect in the diabetic than in the intact animal is in agreement with the results of others(15-17) and suggests that in the normal animal the reverse relationship between insulin and HGF may also exist: insulin hypoglycemia might cause the secretion of HGF and in turn be limited by it. In the depancreatized animal, on the other hand, HGF could not be readily secreted and insulin would be free to show its full effect. Thus, as several investigators have suggested (18-21), HGF would be a true anti-insulin hormone secreted by the pancreas itself and would have a function similar to that of other

anti-insulin mechanisms(22). The secretion of the 2 pancreatic hormones would be mutually regulated by means of their opposing actions on the blood sugar. This hypothesis is being investigated further using cross-circulation experiments.

Conclusions. 1. The hyperglycemia produced by HGF and by epinephrine in the depancreatized dog with ketosis is greater in animals with mild ketosis than in animals with severe ketosis. 2. Since ketosis is believed to increase as liver glycogen decreases these results suggest that the hyperglycemic response to HGF and epinephrine depends upon the amount of liver glycogen present. 3. In the well controlled depancreatized dog without ketosis, on the other hand, the hyperglycemic effect of HGF is greater than in the normal animal, suggesting that in the presence of the pancreas, the action of HGF is limited by the secretion of insulin. 4. Similarly, in the well controlled depancreatized dog without ketosis, the hypoglycemic effect of insulin is greater than in the normal animal, suggesting that in

the presence of the pancreas the action of insulin is limited by the secretion of HGF. 5. It is suggested that HGF and insulin might be 2 mutually regulated pancreatic hormones and that their balanced secretion might be an important factor in the maintenance of a normal blood sugar concentration.

The guidance of Dr. A. H. Ryan in the statistical calculations and interpretation is gratefully acknowledged.

1. Foà, P. P., and Weinstein, H. R., *Am. J. Physiol.*, 1950, v163, 711(P); *Fed. Proc.*, 1951, v10, 43.
2. Greenberg, L. A., and Lester, D., *J. Biol. Chem.*, 1944, v154, 177; 1948, v174, 903.
3. Foà, P. P., and Weinstein, H. R., *Am. J. Physiol.*, 1950, v163, 759(P).
4. Folin, O., and Malmrose, M., *J. Biol. Chem.*, 1929, v83, 115.
5. Foà, P. P., Berger, S., Santamaria, L., Smith, J. A., and Weinstein, H. R., *Science*, in press.
6. Fisher, R. A., *Statistical Methods for Research Workers*, Oliver and Boyd, Edinburgh, 1938.
7. Foà, P. P., *Chicago Medical School Quart.*, 1951, v13, 1.
8. Sutherland, E. W., *Recent Progress in Hormone Res.*, 1950, v5, 441.

9. Weisberg, H. F., Caren, R., Huddleston, B., and Levine, R., *Amer. J. Physiol.*, 1949, v159, 98.
10. Pincus, I. J., *J. Clin. Endocrin.*, 1950, v10, 556.
11. ———, *Proc. Soc. Exp. Biol. and Med.*, 1950, v74, 377.
12. Zunz, E., and La Barre, J. A., *Compt. rend. Soc. de Biol.*, 1927, v96, 421.
13. Anderson, E., and Long, J. A., *Endocrinology*, 1947, v40, 92.
14. Foà, P. P., Weinstein, H. R., and Smith, J. A., *Am. J. Physiol.*, 1949, v157, 197.
15. Houssay, B. A., Lewis, J. T., and Foglia, V. G., *Rev. Soc. Argentina de Biol.*, 1928, v4, 859.
16. Anderson, E., Lindner, E., and Sutton, V., *Am. J. Physiol.*, 1947, v149, 350.
17. Bornstein, J., *Aust. J. Exp. Biol. and Med. Sci.*, 1950, v28, 87.
18. Thorogood, E., and Zimmermann, B., *Endocrinology*, 1945, v37, 191.
19. Gaede, K., Ferner, H., and Kastrup, H., *Klin. Woch.*, 1950, v28, 388.
20. Rodriguez-Candela, J. L., *J. Clin. Endocrin. and Metab.*, 1952, v12, 245.
21. Rodriguez-Candela, J. L., and Christensen-Konig, W., *Trabajos del Inst. Nacional de Ciencias Méd.* (Madrid), 1950, v18, 31.
22. Somogyi, M., *Endocrinology*, 1950, v47, 436.

Received July 14, 1952. P.S.E.B.M., 1952, v80.

Measurements of Radioisotopes in Blood Applied to Determinations of the True Hematocrit.* (19716)

W. D. ARMSTRONG, LEON SINGER, AND BRYANT R. DUNSHEE.

From the Department of Physiological Chemistry, University of Minnesota Medical School, Minneapolis.

A convenient and accurate technic for sample preparation for use in measurement of concentrations of soft beta-ray emitting radioisotopes in blood is required in clinical and experimental investigations. Solid samples, especially at or near "infinite thickness," prepared by the isolation of a precipitate of the radioactive ion give reproducible results(1,2). However, their preparation requires consider-

able time and the counting rate of the sample is lowered by absorption of beta-rays by the sample. Measurement of radioisotopes in liquid samples(3,4) exposed to a thin-window counter has been recommended. Such liquid samples, like thick solid samples, reduce the counting rate by self-absorption, thus necessitating the administration of large amounts of labeled isotopes. Liquid samples suffer the additional disadvantage of possible evaporation, unless covered during counting, and are easily spilled.

Rapid and simple methods for sample preparation, particularly applicable to blood containing beta-ray emitters of low energy, have been developed and tested. These procedures

* Supported by grants from the Research Grants Division, U. S. Public Health Service, and the Graduate School of the University of Minnesota. The radiocalcium and radiosodium used in the experiments were obtained from the Oak Ridge National Laboratory on allocation from the U. S. Atomic Energy Commission.